MOLECULAR PATHOGENESIS OF HEPATOCELLULAR CARCINOMA
Metodieva SN
*Corresponding Author: Corresponding Author: S. Nikolova Metodieva, Department of Medical Genetics, Medical Faculty, Medical University Sofia, 2 Zdrave str., 1413, Sofia, Bulgaria; Tel/Fax: + 359-2-9520-357; E-mail: svetlana.metodieva@ yahoo.com
page: 15

AFLATOXIN-MEDIATED CARCINOGENESIS

 

The aflatoxins are among the most potent genotoxic agents known [19]. Aflatoxin B1 (AFB1) is produced by the fungi Aspergillus flavus and Aspergillus parasiticus, and contaminates improperly stored rice, corn, and peanuts [8]. It induces various chromosomal aberrations, unsched uled DNA synthesis and chromosomal strand breaks in human cells [19]. Aflatoxin B1 is metabolized by hepatic cytochrome p450 to exo-8,9-epoxide, which is mutagenic [1]. After conversion, AFB1-8,9-epoxide can react with guanine nucleotides in the hepatocyte DNA to form a number of adducts capable of forming subsequent repair-resistant adducts, depurination, or of leading to error-prone DNA repair that results in single-strand breaks, base pair substitutions, or frame shift mutations. The most prevalent aflatoxin-nucleic acid adduct is AFB-N7-guanine, and mispairing of the adduct may induce both transversion and transition mutations [19].

Environmental exposure to hepatic carcinogen AFB1 may cause a specific missense mutation in codon 249 of the p53 tumor-suppressor gene. The most prevalent muta tion induced by aflatoxin in the p53 gene is a GC>TA transversion (arginine.serine alteration in the p53 pro tein) in the third nucleotide of codon 249 [1]. The fre quency of codon 249 mutations parallels the level of afla toxin exposure [20]. Very importantly, AFB1 has syner gistic effects with the HBV that may sensitize hepatocytes to the carcinogenic effects of aflatoxin [21]. Due to the similar frequency of mutations in p53 in regions with a high incidence of HBV and varying aflatoxin exposure, it has been suggested that alterations in p53 independent of the codon 249 mutation may play an important role in HBV-associated HCC. It has been demonstrated that codon 249 is not the major site of adduction by AFB1; adducts were detected in codons in exons 7 and 8. The G>T transversions at the third base of codon 249 were preferentially induced in vitro in human hepatocarcinoma cells incubated with AFB1, although G>T and C>A trans versions were also observed in adjacent codons [20].

The electrophilic intermediates (epoxides), resulting from conversion of AFB1, are detoxified mainly by glutathione-S-transferase (GST) that catalyze the conjuga tion of reduced glutathione to electrophilic centers of the substrates. Activity of the pathways that detoxify the muta genic AFB1-8,9-exo-epoxide can be decreased by poly morphisms of the GST gene [22].

It has been suggested that interaction among the geno types of three enzymes associated with AFB1 metabolism and DNA repair [GSTM1 null genetic polymorphism, megakaryocyte-associated tyrosine kinase (HYL1*2) genotype YH/HH) and X-ray repair complementing defec tive repair in Chinese hamster cells (XRCC1) genotype AG/GG] and AFB1 intake may have functional signifi cance in the repair of AFB1-induced genetic lesions [23].





Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006